- Trials with a EudraCT protocol (4)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
4 result(s) found for: Lung bud.
Displaying page 1 of 1.
EudraCT Number: 2006-002094-46 | Sponsor Protocol Number: FB/PS/14/160/06 | Start Date*: 2006-06-26 |
Sponsor Name:Chiesi Farmaceutici S.p.A. | ||
Full Title: Single blind, randomized, crossover, repeated dose, pharmacokinetic and pharmacodynamic interaction study of CHF 4226 HFA and Extra-fine BUD HFA in asthmatic patients | ||
Medical condition: Asthmatics patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-004926-17 | Sponsor Protocol Number: P04879 | Start Date*: 2015-04-16 |
Sponsor Name:Schering-Plough S.A.de C.V. | ||
Full Title: OPEN LABEL, 12-WEEK CLINICAL TRIAL TO ASSESS EFFICACY, SAFETY, TREATMENT ADHERENCE AND QUALITY OF LIFE IMPACT ON MOMETASONE FUROATE DRY POWDER 400 MCG ONCE DAILY IN PERSISTENT MILD-MODERATE ASTHMAT... | ||
Medical condition: Persistent asthma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2008-005707-26 | Sponsor Protocol Number: CCD-0812-PR-0003 | Start Date*: 2008-12-30 | |||||||||||
Sponsor Name:Chiesi Farmaceutici SpA | |||||||||||||
Full Title: Effect of beclomethasone dipropionate/formoterol fumarate (BDP+FF) administered as a fixed pMDI combination on lung impedance and exhaled nitric oxide in comparison with the fixed combination of bu... | |||||||||||||
Medical condition: Bronchial Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000038-11 | Sponsor Protocol Number: RA/PR/033012/002/05 | Start Date*: 2006-07-10 | |||||||||||
Sponsor Name:CHIESI Farmaceutici S.p.A | |||||||||||||
Full Title: EVALUATION OF THE EFFICACY, SAFETY AND TOLERABILITY OF THE CONCURRENT ADMINISTRATION OF CHF 4226 HFA pMDI AND EXTRAFINE BUDESONIDE HFA pMDI, BOTH GIVEN ONCE OR TWICE DAILY (2μg + 200μg qd or 1μg + ... | |||||||||||||
Medical condition: Moderate persistent asthma sub optimally controlled on existing therapy. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
